Multicentric studies

Multicentric studies

  1. International study controlled by medicine group Süddeutsche Hämoblastosegruppe: CML study IIIA. Prospective controlled study for optimalization of therapy in chronic myeloid leukemia (Mayer).
  2. International study controlled by Searle, USA: Mobilization of PBSC with Cyklophosphamide, Etoposide, and SC – 70935 or G-CSF in Lymphoma Patients (Mayer).
  3. Multicentric study –therapy of acute lymphoblastic leukemia in adults 06/99 (Doubek)
  4. International myeloma trial. (Adam)
  5. 4W study- high-dose treatment in multiple myeloma with autologous stem cell transplantation and following maintenance therapy (Adam)
  6. Zolendronat P010. A randomized, double-blind multimember, comparative trial of i.v. zolendronate (4 mg or 8 mg) versus i.v. aredia (90 mg), as an adjunct to standard therapies in the treatment of multiple myeloma and breast cancer patients with cancer related bone lesions. (R. Hájek).
  7. Randomized study in patients with progressive tumor involvement who suffer from weight loss and anorexia and are treated with fixed or individualized doses of megestrol with the goal of the quality of life evaluation (Tomíška)
  8. Comparison of a combination of fluoride and raloxifene vs. fluoride alone in the treatment of postmenopausal osteoporosis – H3S-MC-GGHU. (Fojtík)
  9. Successive celecoxib efficacy and safety studies: in osteoarthritis (SUCCESS-1). (Fojtík)
  10. Comparative study of effectiveness and tolerance of LMW-Heparin SANDOZ CERTOPARIN 2 x 8000 E aXa s.c. versus unfractioned Heparin 20 h i.v. in patients with phlebography-proven deep venous thrombosis (Žáčková)
  11. A Double-Blind, Randomized Controlled Study - Methotrexate Plus Sandimun Neoral versus Methotrexate Plus Placebo in Subjects with Early Severe Rheumatoid Arthritis. (Fojtík)
  12. Vancomycin versus placebo in persistently febrile granulocytopenic patients given piperacillin/tazobactam (Obořilová)
  13. German Hodgkin Lymphoma Group - Study protocols for primary treatment HD10, HD11, HD12. (Král)
  14. MK-0991 Versus (Amphotericin B) Liposome for Injection for Empirical Therapy in Febrile, Neutropenic Patients. Multicentric, double blind, randomized study, evaluating the safety, tolerance and effectiveness of MK-0991 (caspofudin acetat-Cansidas) versus liposomal amphotericin B (AmBisome) in empiric therapy of patients with febrile neutropenia (Mayer)
  15. Erytropoetin study: Open randomized parallel multicentric study evaluating the efficacy and safety of erytropoetin (NeoRecormon) once-a-week dosing versus the standard three-times-a-week dosing of NeoRecormon – as a therapy of anemic patients with low-grade non-Hodgkin’s lymphoma, chronic lymphatic leukemias or in multiple myeloma. (Mayer)

zde může být Vaše reklama logo Zbrojovky Brno logo Lékaři bez hranic
Kalendář akcí
Mo Tu We Th Fr Sa Su


change text size

Jihlavská 20, 625 00 Brno
+420 532 23 1111

NIAHOSM ISO 9001:2008 ISO 14001:2001